HighTower Advisors LLC Sells 23,863 Shares of IQVIA Holdings Inc. (NYSE:IQV)

HighTower Advisors LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,168 shares of the medical research company's stock after selling 23,863 shares during the quarter. HighTower Advisors LLC owned about 0.07% of IQVIA worth $23,221,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of IQV. Impax Asset Management Group plc raised its stake in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock valued at $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Assetmark Inc. raised its stake in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Covestor Ltd raised its stake in shares of IQVIA by 34.4% during the third quarter. Covestor Ltd now owns 246 shares of the medical research company's stock valued at $59,000 after purchasing an additional 63 shares in the last quarter. Apollon Wealth Management LLC raised its position in IQVIA by 9.6% in the third quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company's stock worth $1,155,000 after acquiring an additional 427 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in IQVIA in the third quarter worth about $230,000. 89.62% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

IQV has been the topic of several research reports. UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, William Blair restated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Stock Down 0.9 %

NYSE:IQV traded down $1.75 on Wednesday, hitting $186.80. 1,007,776 shares of the company's stock traded hands, compared to its average volume of 1,227,562. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $256.34. The firm has a 50-day moving average price of $196.06 and a 200-day moving average price of $209.52. The company has a market cap of $32.93 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.